Moclobemide attenuates anoxia and glutamate-induced neuronal damage in vitro independently of interaction with glutamate receptor subtypes

Brain Research

Volumn 1138, Issue 1, 2007, Pages 30-38

  Verleye, Marc ^a   Steinschneider, Remy ^b   Bernard, François Xavier ^b   Gillardin, Jean Marie ^a  

^a Service de Pharmacologie   (France)

^b BIOalternatives ^*  (France)

Author keywords

Anoxia; l Glutamate; Moclobemide; Neuronal astroglial culture; Neuroprotection; Rat

Indexed keywords

CALCIUM; CALCIUM CHANNEL; EXCITATORY AMINO ACID; GLUTAMATE RECEPTOR; GLUTAMIC ACID; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; POTASSIUM; RECEPTOR SUBTYPE; SODIUM; SODIUM CHANNEL; VERATRIDINE;

AEROBIC METABOLISM; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BINDING AFFINITY; BRAIN CORTEX; BRAIN HYPOXIA; BRAIN ISCHEMIA; CELL SURVIVAL; CELL SWELLING; CONCENTRATION (PARAMETERS); CULTURE MEDIUM; DEGENERATIVE DISEASE; EXTRACELLULAR SPACE; IC 50; IN VITRO STUDY; MOLECULAR INTERACTION; NERVE CELL CULTURE; NERVE CELL LESION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT;

ANIMALS; ANOXIA; ASTROCYTES; CALCIUM; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; GLUTAMIC ACID; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITORS; NEURONS; NEUROPROTECTIVE AGENTS; POTASSIUM; RATS; RATS, WISTAR; RECEPTORS, GLUTAMATE; SODIUM; VERATRIDINE;

RATTUS;

EID: 33847202964     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.12.089     Document Type: Article

References (60)

1. Alexopoulos G.S., Meyers B.S., Young R.C., Campbell S., Silbersweig D., and Charlson M. Vascular depression' hypothesis. Arch. Gen. Psychiatry 54 (1997) 915-922
2. Alkadhi K.A., and Tian L.M. Veratridine-enhanced persistent sodium current induces bursting in CA1 pyramidal neurons. Neuroscience 71 (1996) 625-632
3. Alper G., Girgin F.K., Ozgonul M., Mentes G., and Ersoz B. MAO inhibitors and oxidant stress in aging brain tissue. Eur. Neuropsychopharmacol. 9 (1999) 247-252
4. Ames B.N., and Shigenaga M.K. Oxidants are a major contributor to aging. Ann. N. Y. Acad. Sci. 663 (1992) 85-96
5. Appel S.H. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease. Ann. Neurol. 10 (1981) 499-505
6. Ay H., Ay I., Koroshetz W.J., and Finklestein S.P. Potential usefulness of basic fibroblast growth factor as a treatment for stroke. Cerebrovasc. Dis. 9 (1999) 131-135
7. 3H]MDL 105,519, a high-affinity radioligand for the N-methyl-d-aspartate receptor-associated glycine recognition site. J. Pharmacol. Exp. Ther. 279 (1996) 62-68
8. Benveniste H., Drejer J., Schousboe A., and Diemer N.H. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J. Neurochem. 43 (1984) 1369-1374
9. Boland A., Gerardy J., Mossay D., Delapierre D., and Seutin V. Pirlindole and dehydropirlindole protect rat cultured neuronal cells against oxidative stress-induced cell death through a mechanism unrelated to MAO-A inhibition. Br. J. Pharmacol. 135 (2002) 713-720
10. Boland A., Gerardy J., Mossay D., and Seutin V. Pre- and post-treatment with pirlindole and dehydropirlindole protects cultured brain cells against nitric oxide-induced death. Eur. J. Pharmacol. 463 (2003) 163-175 466, 21-30
11. Bonde C., Noraberg J., Noer H., and Zimmer J. Ionotropic glutamate receptors and glutamate transporters are involved in necrotic neuronal cell death induced by oxygen-glucose deprivation of hippocampal slice cultures. Neuroscience 136 (2005) 779-794
12. Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 9 (2003) 97-140
13. Bonnet U., Leniger T., and Wiemann M. Moclobemide reduces intracellular pH and neuronal activity of CA3 neurones in guinea-pig hippocampal slices-implication for its neuroprotective properties. Neuropharmacology 39 (2000) 2067-2074
14. Burkard W.P., Bonetti E.P., Da Prada M., Martin J.R., Polc P., Schaffner R., Scherschlicht R., Hefti F., Muller R.K., and Wyss P.C. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J. Pharmacol. Exp. Ther. 248 (1989) 391-399
15. Cesura A.M., Kettler R., Imhof R., and Da Prada M. Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide. Psychopharmacology (Berlin) 106 (1992) S15-S16 (Suppl.)
16. Choi D.W. Ionic dependence of glutamate neurotoxicity. J. Neurosci. 7 (1987) 369-379
17. Choi D.W. Excitotoxic cell death. J. Neurobiol. 23 (1992) 1261-1276
18. Choi D.W., Koh J.Y., and Peters S. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J. Neurosci. 8 (1988) 185-196
19. Chung R.S., McCormack G.H., King A.E., West A.K., and Vickers J.C. Glutamate induces rapid loss of axonal neurofilament proteins from cortical neurons in vitro. Exp. Neurol. 193 (2005) 481-488
20. Da Prada M., Kettler R., Keller H.H., Burkard W.P., and Haefely W.E. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors. J. Neural Transm., Suppl. 28 (1989) 5-20
21. Da Prada M., Kettler R., Keller H.H., Burkard W.P., Muggli-Maniglio D., and Haefely W.E. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J. Pharmacol. Exp. Ther. 248 (1989) 400-414
22. Da Prada M., Pieri L., Cesura A.M., and Kettler R. The pharmacology of moclobemide. Rev. Contemp. Pharmacother. 5 (1994) 1-18
23. Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol. Ther. 81 (1999) 163-221
24. Edelstein S.B., and Breakefield X.O. Monoamine oxidases A and B are differentially regulated by glucocorticoids and "aging" in human skin fibroblasts. Cell. Mol. Neurobiol. 6 (1986) 121-150
25. Galizzi J.P., Qar J., Fosset M., Van Renterghem C., and Lazdunski M. Regulation of calcium channels in aortic muscle cells by protein kinase C activators (diacylglycerol and phorbol esters) and by peptides (vasopressin and bombesin) that stimulate phosphoinositide breakdown. J. Biol. Chem. 262 (1987) 6947-6950
26. Gallarda T. Depression and organic brain diseases in the elderly. Psychol. Neuropsychiatr. Vieil. 2 Suppl. 1 (2004) S43-S51
27. Glass T.F., Reeves B., and Sharp F.R. The impact of excitotoxic blockade on the evolution of injury following combined mechanical and hypoxic insults in primary rat neuronal culture. Neurobiol. Dis. 17 (2004) 378-384
28. Gorgias N., Maidatsi P., Tsolaki M., Alvanou A., Kiriazis G., Kaidoglou K., and Giala M. Hypoxic pretreatment protects against neuronal damage of the rat hippocampus induced by severe hypoxia. Brain Res. 714 (1996) 215-225
29. Greene J.G., and Greenamyre J.T. Exacerbation of NMDA, AMPA, and l-glutamate excitotoxicity by the succinate dehydrogenase inhibitor malonate. J. Neurochem. 64 (1995) 2332-2338
30. Haefely W., Burkard W.P., Cesura A., Colzi A., Kettler R., Lorez H.P., Martin J.R., Moreau J.L., Richards J.G., and Schaffner R. Pharmacology of moclobemide. Clin. Neuropharmacol. 16 Suppl. 2 (1993) S8-S18
31. Jabaudon D., Scanziani M., Gahwiler B.H., and Gerber U. Acute decrease in net glutamate uptake during energy deprivation. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 5610-5615
32. + ionophore in neuroblastoma cells. Interactions with neurotoxins. J. Biol. Chem. 253 (1978) 7383-7392
33. 2+ is coupled with reactive oxygen species generation in cultured hippocampal neurons but not in astrocytes. J. Neurosci. Res. 79 (2005) 262-271
34. Kettler R., Da Prada M., and Burkard W.P. Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats. Acta Psychiatr. Scand., Suppl. 360 (1990) 101-102
35. Koh J.Y., and Choi D.W. Selective blockade of non-NMDA receptors does not block rapidly triggered glutamate-induced neuronal death. Brain Res. 548 (1991) 318-321
36. Krishnan M., Mast B.T., Ficker L.J., Lawhorne L., and Lichtenberg P.A. The effects of preexisting depression on cerebrovascular health outcomes in geriatric continuing care. J. Gerontol., A Biol. Sci. Med. Sci. 60 (2005) 915-919
37. Li Y.F., Liu Y.Q., Huang W.C., and Luo Z.P. Cytoprotective effect is one of common action pathways for antidepressants. Acta Pharmacol. Sin. 24 (2003) 996-1000
38. Lipton P. Ischemic cell death in brain neurons. Physiol. Rev. 79 (1999) 1431-1568
39. Maher P., and Davis J.B. The role of monoamine metabolism in oxidative glutamate toxicity. J. Neurosci. 16 (1996) 6394-6401
40. Meli E., Picca R., Attucci S., Cozzi A., Peruginelli F., Moroni F., and Pellegrini-Giampietro D.E. Activation of mGlu1 but not mGlu5 metabotropic glutamate receptors contributes to postischemic neuronal injury in vitro and in vivo. Pharmacol. Biochem. Behav. 73 (2002) 439-446
41. 3H]kainic acid binding sites in rat CNS as determined by autoradiography. Brain Res. 252 (1982) 91-100
42. Monaghan D.T., Bridges R.J., and Cotman C.W. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 29 (1989) 365-402
43. 3H]alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and a filtration assay. Neurochem. Res. 12 (1987) 775-781
44. Naarding P., Schoevers R.A., Janzing J.G., Jonker C., Koudstaal P.J., and Beekman A.T. A study on symptom profiles of late-life depression: the influence of vascular, degenerative and inflammatory risk-indicators. J. Affect. Disord. 88 (2005) 155-162
45. Nicholls D.G. Mitochondrial dysfunction and glutamate excitotoxicity studied in primary neuronal cultures. Curr. Mol. Med. 4 (2004) 149-177
46. Nicotra A., Pierucci F., Parvez H., and Senatori O. Monoamine oxidase expression during development and aging. Neurotoxicology 25 (2004) 155-165
47. Nozaki K., Finklestein S.P., and Beal M.F. Basic fibroblast growth factor protects against hypoxia-ischemia and NMDA neurotoxicity in neonatal rats. J. Cereb. Blood Flow. Metab. 13 (1993) 221-228
48. Olney J.W. New insights and new issues in developmental neurotoxicology. Neurotoxicology 23 (2002) 659-668
49. Oreland L., and Gottfries C.G. Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type. Prog. Neuro-psychopharmacol. Biol. Psychiatry 10 (1986) 533-540
50. Reisberg B., Borenstein J., Salob S.P., Ferris S.H., Franssen E., and Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J. Clin. Psychiatry 48 (1987) 9-15
51. Ruegg U.T., Doyle V.M., Zuber J.F., and Hof R.P. A smooth muscle cell line suitable for the study of voltage sensitive calcium channels. Biochem. Biophys. Res. Commun. 130 (1985) 447-453
52. 3H]CGP 39653: a new N-methyl-d-aspartate antagonist radioligand with low nanomolar affinity in rat brain. Eur. J. Pharmacol. 192 (1991) 19-24
53. Steinschneider R., Delmas P., Nedelec J., Gola M., Bernard D., and Boucraut J. Appearance of neurofilament subunit epitopes correlates with electrophysiological maturation in cortical embryonic neurons cocultured with mature astrocytes. Brain Res. Dev. Brain Res. 95 (1996) 15-27
54. Troncoso P., Dominguez J., Martinez L., and Zambrano N. Oxidative damage markers in a renal ischemic-reperfusion model: the protective effect of monoamine oxidase inhibition. Transplant. Proc. 27 (1995) 1836-1838
55. Ulugol A., Karadag H.C., Dokmeci D., al Khatib I., and Dokmeci I. The protective effect of moclobemide against hypoxia-induced lethality in mice is not due to a decrease in body temperature. Pharmacol. Biochem. Behav. 51 (1995) 245-247
56. 3H]TCP) binds to two different sites in rat brain. Localization by autoradiographic and biochemical techniques. Brain Res. 378 (1986) 133-141
57. Volbracht C., van Beek J., Zhu C., Blomgren K., and Leist M. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. Eur. J. Neurosci. 23 (2006) 2611-2622
58. Watkins J.C., Krogsgaard-Larsen P., and Honore T. Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol. Sci. 11 (1990) 25-33
59. Weyler W., Hsu Y.P., and Breakefield X.O. Biochemistry and genetics of monoamine oxidase. Pharmacol. Ther. 47 (1990) 391-417
60. Yamakage M., and Namiki A. Calcium channels-basic aspects of their structure, function and gene encoding; anesthetic action on the channels - a review. Can. J. Anaesth. 49 (2002) 151-164